Clovis shares double on positive early data for lung cancer drug

[riky]

Clovis shares double on positive early data for lung cancer drug

(Reuters) - Clovis Oncology said initial results of an early-stage trial of its experimental lung cancer drug showed a reduction in tumor size, prompting investors to more than double the company's market value on Monday. The experimental therapy, named CO-1686, aims to treat non-small-cell lung cancer (NSCLC) in patients with a mutation in gene T790M. "(The) data was extremely impressive and we believe further highlights the drug's paradigm changing potential for at least refractory NSCLC patients with (this) mutation," Leerink Swann analyst Marko Kozul wrote in a note. ...

Source: You are not allowed to view links. Register or Login